Schnabolk Gloriane, Coughlin Beth, Joseph Kusumam, Kunchithapautham Kannan, Bandyopadhyay Mausumi, O'Quinn Elizabeth C, Nowling Tamara, Rohrer Bärbel
Research Service, Ralph H. Johnson VA Medical Center, Charleston, South Carolina, United States.
Department of Ophthalmology, Medical University of South Carolina, Charleston, South Carolina, United States.
Invest Ophthalmol Vis Sci. 2015 Jan 15;56(3):1850-63. doi: 10.1167/iovs.14-15910.
Complement factor B (CFB) is a required component of the alternative pathway (AP) of complement, and CFB polymorphisms are associated with age-related macular degeneration (AMD) risk. Complement factor B is made in the liver, but expression has also been detected in retina and retinal pigment epithelium (RPE)-choroid. We investigated whether production of CFB by the RPE can promote AP activation in mouse choroidal neovascularization (CNV).
Transgenic mice expressing CFB under the RPE65 promoter were generated and crossed onto factor B-deficient (CFB-KO) mice. Biological activity was determined in vitro using RPE monolayers and in vivo using laser-induced CNV. Contribution of systemic CFB was investigated using CFB-KO reconstituted with CFB-sufficient serum.
Transgenic mice (CFB-tg) expressed CFB in RPE-choroid; no CFB was detected in serum. Cultured CFB-tg RPE monolayers secreted CFB apically and basally upon exposure to oxidative stress that was biologically active. Choroidal neovascularization sizes were comparable between wild-type and CFB-tg mice, but significantly increased when compared to lesions in CFB-KO mice. Injections of CFB-sufficient serum into CFB-KO mice resulted in partial reconstitution of systemic AP activity and significantly increased CNV size.
Mouse RPE cells express and secrete CFB sufficient to promote RPE damage and CNV. This further supports that local complement production may regulate disease processes; however, the reconstitution experiments suggest that additional components may be sequestered from the bloodstream. Understanding the process of ocular complement production and regulation will further our understanding of the AMD disease process and the requirements of a complement-based therapeutic.
补体因子B(CFB)是补体替代途径(AP)的必需成分,CFB基因多态性与年龄相关性黄斑变性(AMD)风险相关。补体因子B在肝脏中产生,但在视网膜和视网膜色素上皮(RPE)-脉络膜中也检测到其表达。我们研究了RPE产生的CFB是否能促进小鼠脉络膜新生血管(CNV)中的AP激活。
构建在RPE65启动子控制下表达CFB的转基因小鼠,并与因子B缺陷(CFB-KO)小鼠杂交。使用RPE单层细胞在体外测定生物活性,并使用激光诱导的CNV在体内测定生物活性。使用补充有足够CFB的血清重建CFB-KO小鼠,研究全身CFB的作用。
转基因小鼠(CFB-tg)在RPE-脉络膜中表达CFB;血清中未检测到CFB。培养的CFB-tg RPE单层细胞在暴露于具有生物活性的氧化应激时,会在顶端和基底分泌CFB。野生型和CFB-tg小鼠的脉络膜新生血管大小相当,但与CFB-KO小鼠的病变相比显著增加。向CFB-KO小鼠注射含有足够CFB的血清导致全身AP活性部分重建,并且CNV大小显著增加。
小鼠RPE细胞表达并分泌足以促进RPE损伤和CNV的CFB。这进一步支持局部补体产生可能调节疾病进程;然而,重建实验表明可能从血液中隔离了其他成分。了解眼部补体产生和调节过程将有助于我们进一步了解AMD疾病进程以及基于补体的治疗要求。